Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Presidio Pharmaceuticals and Numerate have entered into a research collaboration to discover and develop novel small molecule inhibitors of hepatitis C virus or HCV.
Subscribe to our email newsletter
Richard Colonno, chief scientific officer of Presidio, said: “Numerate has a very promising computational approach that we believe will help expand our HCV portfolio in a highly competitive area encumbered by many patents.”